These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21640518)

  • 41. Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.
    Jeremić B; Miličić B; Milisavljevic S
    Clin Transl Oncol; 2012 Aug; 14(8):613-8. PubMed ID: 22855143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer.
    Casas F; Viñolas N; Ferrer F; Agustí C; Sanchez M; Maria Gimferrer J; Lomeña F; Campayo M; Jeremic B
    J Thorac Oncol; 2011 Jan; 6(1):79-85. PubMed ID: 21150466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer.
    Hainsworth JD; Gray JR; Litchy S; Bearden JD; Shaffer DW; Houston GA; Greco FA
    Clin Lung Cancer; 2004 Jul; 6(1):33-42. PubMed ID: 15310415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
    Tada T; Chiba Y; Tsujino K; Fukuda H; Nishimura Y; Kokubo M; Negoro S; Kudoh S; Fukuoka M; Nakagawa K; Nakanishi Y
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):327-31. PubMed ID: 22079726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
    Campeau MP; Herschtal A; Wheeler G; Mac Manus M; Wirth A; Michael M; Hogg A; Drummond E; Ball D
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1371-5. PubMed ID: 19250769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer.
    Jeremic B; Shibamoto Y; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):343-8. PubMed ID: 10760429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
    Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.
    Jeremić B; Miličić B; Milisavljević S
    Clin Transl Oncol; 2013 Sep; 15(9):747-53. PubMed ID: 23359170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients.
    Ball D; Bishop J; Smith J; Crennan E; O'Brien P; Davis S; Ryan G; Joseph D; Walker Q
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):267-72. PubMed ID: 7836079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
    Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
    Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.
    Akerley W; Herndon JE; Lyss AP; Choy H; Turrisi A; Graziano S; Williams T; Zhang C; Vokes EE; Green MR
    Clin Lung Cancer; 2005 Jul; 7(1):47-53. PubMed ID: 16098244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
    Keene KS; Harman EM; Knauf DG; McCarley D; Zlotecki RA
    Am J Clin Oncol; 2005 Jun; 28(3):217-22. PubMed ID: 15923791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
    Wang L; Correa CR; Zhao L; Hayman J; Kalemkerian GP; Lyons S; Cease K; Brenner D; Kong FM
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1383-90. PubMed ID: 18929449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
    Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Randomized trial of hyperfractionated plus accelerated hyperfractionated radiation therapy with or without concomitant chemotherapy for stage IIIA/IIIB non-small-cell lung cancer:A preliminary result].
    Lu J; Wang D; Chen J; Huang K; He X; Feng J
    Zhongguo Fei Ai Za Zhi; 2002 Dec; 5(6):423-6. PubMed ID: 21333221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.